ArticleMolecular biology reports2026
LncRNA DNM3OS suppresses proliferation, invasion, and epithelial-mesenchymal transition in cervical cancer cells via miR-454-3p.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCervical cancer (CC) persists as a major contributor to cancer-related deaths in the female population. Long non-coding RNAs have shown potential as biomarkers in tumors, but the function of DNM3OS in CC is unclear.
objectiveThis study investigates the prognostic value of DNM3OS in CC and its functional effects in tumor cells, aiming to identify a promising biomarker for this cancer.
methodsDNM3OS expression was measured in tumor and normal tissues from 152 patients with CC using RT-qPCR, and its association with progression-free survival and clinical parameters was analyzed. The role of DNM3OS on proliferation, invasion, apoptosis, and epithelial-mesenchymal transition (EMT) in CC cells was examined following overexpression or knockdown. The binding between miR-454-3p and DNM3OS was verified, and functional rescue experiments were conducted by upregulating miR-454-3p.
resultsDNM3OS was significantly downregulated in CC tissues, and its low expression was associated with larger tumor size, lymph node metastasis, and advanced FIGO stage. DNM3OS acted as an independent factor for prognosis, with its low expression correlating with poor progression-free survival in CC patients. DNM3OS directly bound to miR-454-3p. Overexpression of DNM3OS suppressed the proliferation, EMT, and invasion of CC cells, while promoting apoptosis. These antitumor effects were partially counteracted by miR-454-3p overexpression.
conclusionsDownregulation of DNM3OS predicts poor prognosis in CC, and DNM3OS suppresses the biological behavior of tumor cells by sponging miR-454-3p. DNM3OS may serve as a prognostic biomarker for CC.
Indexed as
Identifiers
42525155What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.